Hypothermic oxygenated perfusion (HOPE) against cancer recurrence in HCC liver transplantation - International multicentre parallel group interventional RCT
Phase: Phase IV clinical trials
Principal Investigator: Prof. Mazzaferro Vincenzo
Main Facility: Chirurgia Generale Oncologica 1 – Epato-Gastro-Pancreatica e Trapianto di Fegato
Pathologies: Hepatocellular carcinoma (HCC)
ClinicalTrials.gov: Read more about clinical trials
This international multicentre randomized controlled trial (HOPE4Cancer) evaluates whether hypothermic oxygenated liver perfusion (HOPE) applied before liver transplantation can reduce the risk of hepatocellular carcinoma (HCC) recurrence after transplantation.
HOPE is a machine perfusion technique in which the donor liver is perfused with an oxygenated solution under hypothermic conditions before implantation, aiming to improve graft quality and reduce ischemia-reperfusion injury.
Approximately 220 adult patients with HCC awaiting liver transplantation will be randomized to receive either a liver treated with HOPE or a graft preserved with standard static cold storage. Patients will be followed for at least 24 months after transplantation.
The primary endpoint is recurrence-free survival after transplantation, while secondary outcomes include HCC recurrence, HCC-related mortality, death from other causes, and several biological and graft-function markers.
Last update: 20/04/2026